225 related articles for article (PubMed ID: 12600190)
1. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
Stajszczyk M
Pol Arch Med Wewn; 2002 Sep; 108(3):915-24. PubMed ID: 12600190
[No Abstract] [Full Text] [Related]
2. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
3. [New paradigms in the regulation of bone metabolism].
Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.
Hofbauer LC
Eur J Endocrinol; 1999 Sep; 141(3):195-210. PubMed ID: 10474114
[No Abstract] [Full Text] [Related]
5. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
6. OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis.
Wittersheim E; Mesquita M; Demulder A; Guns M; Louis O; Melot C; Dratwa M; Bergmann P
Clin Biochem; 2006 Jun; 39(6):617-22. PubMed ID: 16530745
[TBL] [Abstract][Full Text] [Related]
7. Genetic regulation of osteoclast development and function.
Teitelbaum SL; Ross FP
Nat Rev Genet; 2003 Aug; 4(8):638-49. PubMed ID: 12897775
[TBL] [Abstract][Full Text] [Related]
8. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance.
Lubberts E; van den Bersselaar L; Oppers-Walgreen B; Schwarzenberger P; Coenen-de Roo CJ; Kolls JK; Joosten LA; van den Berg WB
J Immunol; 2003 Mar; 170(5):2655-62. PubMed ID: 12594294
[TBL] [Abstract][Full Text] [Related]
9. Interactions between immune and bone cells: new insights with many remaining questions.
Lorenzo J
J Clin Invest; 2000 Sep; 106(6):749-52. PubMed ID: 10995785
[No Abstract] [Full Text] [Related]
10. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
Swanson C; Lorentzon M; Conaway HH; Lerner UH
Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
[TBL] [Abstract][Full Text] [Related]
11. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
Evans CE; Mylchreest S; Andrew JG
BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
[TBL] [Abstract][Full Text] [Related]
12. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones.
Woo KM; Choi Y; Ko SH; Ko JS; Oh KO; Kim KK
Exp Mol Med; 2002 Nov; 34(5):347-52. PubMed ID: 12526098
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3.
Voskaridou E; Terpos E
Eur J Haematol; 2005 Apr; 74(4):359-61. PubMed ID: 15777350
[No Abstract] [Full Text] [Related]
15. Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?
Coetzee M; Kruger MC
South Med J; 2004 May; 97(5):506-11. PubMed ID: 15180028
[TBL] [Abstract][Full Text] [Related]
16. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
[TBL] [Abstract][Full Text] [Related]
17. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand.
Schneeweis LA; Willard D; Milla ME
J Biol Chem; 2005 Dec; 280(50):41155-64. PubMed ID: 16215261
[TBL] [Abstract][Full Text] [Related]
18. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
19. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Boyle WJ; Riggs BL
J Bone Miner Res; 2000 Jan; 15(1):2-12. PubMed ID: 10646108
[TBL] [Abstract][Full Text] [Related]
20. OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?
Manganelli P; Giuliani N; Fietta P; Mancini C; Lazzaretti M; Pollini A; Quaini F; Pedrazzoni M
Clin Rheumatol; 2005 Jun; 24(3):296-300. PubMed ID: 15583970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
